Tyrosine Kinase Inhibitors Outperform Immune Checkpoint Inhibitors in Bone-Predominant Metastatic Renal Cell Carcinoma: A Multicenter Real-World Analysis.

J Cancer · 2025 · PMC12595247 · PMID 41210691

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significanceP = 0.075so close (0.05 < p ≤ 0.1)

Although this difference did not reach statistical significance (log-rank test, P = 0.075), it suggests a potential benefit of TKIs in delaying disease progression.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.